The introduction of immunotherapy into breast cancer treatment protocols raises questions about cost-effectiveness and accessibility. Its high cost may limit availability in certain healthcare settings, presenting challenges for widespread adoption. Ongoing analysis is needed to evaluate its long-term economic impact compared to traditional therapies and its potential to become a standard treatment option for breast cancer.
- Log in or register to contribute
Contribute to three or more articles across any domain to qualify for the Contributor badge. Please check back tomorrow for updates on your progress.